TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avricore Health ( (TSE:AVCR) ) has provided an update.
Avricore Health’s HealthTab platform is being utilized in a new pilot program by Barts Health NHS Trust to deliver cholesterol-lowering injections through community pharmacies in the UK. This initiative marks a significant expansion of HealthTab’s role from primary to secondary prevention, integrating with the Ortus-iHealth platform to connect pharmacy-generated results directly into hospital systems. Supported by a British Heart Foundation grant, the pilot aims to decentralize cardiovascular therapy, reduce hospital burdens, and enhance long-term lipid management, aligning with NHS policies to increase the role of community pharmacies in chronic condition management.
Spark’s Take on TSE:AVCR Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCR is a Neutral.
Avricore Health’s strong financials and strategic corporate developments are offset by high valuation concerns and neutral technical indicators. The company’s financial stability and growth potential are promising, but profitability and valuation require attention.
To see Spark’s full report on TSE:AVCR stock, click here.
More about Avricore Health
Avricore Health Inc. operates in the healthcare industry, focusing on providing innovative health solutions through its HealthTab platform. The company’s primary service involves integrating diagnostic and therapeutic workflows in community pharmacies, with a market focus on enhancing chronic condition management and preventive care.
Average Trading Volume: 55,965
Technical Sentiment Signal: Sell
Current Market Cap: C$5.57M
For detailed information about AVCR stock, go to TipRanks’ Stock Analysis page.